| |
| |
|
| Insider
Information: |
Azab Mohammad |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
194,105 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$81,742 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
194,105 |
|
|
| Total
Value |
$81,742 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
0
|
|
Stock
price went up :
|
3
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
3.0
|
0.0
|
| Percentage
Gain/Loss : |
 44.5%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Novelion Therapeutics Inc |
NVLN |
Exec VP-R&D, CMO |
2005-05-24 |
1,200 |
|
0 |
Premium* |
|
|
Astex Pharmaceuticals Inc |
ASTX |
Chief Medical Officer |
2013-10-11 |
0 |
2013-10-11 |
0 |
Premium* |
|
|
Xenon Pharmaceuticals Inc. |
XENE |
|
2023-12-19 |
74,225 |
2015-01-08 |
0 |
Premium* |
|
|
Durect Corp |
DRRX |
Director |
2022-05-24 |
60,000 |
2022-05-16 |
0 |
Premium* |
|
|
Lisata Therapeutics Ord Shs |
LSTA |
Director |
2024-01-09 |
58,680 |
2022-09-15 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LSTA |
Lisata Therapeutics Ord S... |
Director |
– • – |
2024-01-09 |
4 |
A |
$0.00 |
$0 |
D/D |
19,480 |
58,680 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
|
– • – |
2023-12-19 |
4 |
OE |
$9.85 |
$42,552 |
D/D |
4,320 |
74,225 |
0 |
- |
|
| LSTA |
Lisata Therapeutics Ord S... |
Director |
– • – |
2023-01-09 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
39,200 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2022-12-12 |
4 |
OE |
$2.68 |
$8,270 |
D/D |
3,086 |
69,905 |
0 |
- |
|
| LSTA |
Lisata Therapeutics Ord S... |
Director |
– • – |
2022-09-15 |
4 |
A |
$6.25 |
$120,000 |
D/D |
19,200 |
19,200 |
0 |
- |
|
| DRRX |
Durect Corp |
Director |
– • – |
2022-05-24 |
4 |
B |
$0.38 |
$11,638 |
D/D |
30,000 |
60,000 |
2.39 |
% |
|
| DRRX |
Durect Corp |
Director |
– • – |
2022-05-17 |
4 |
B |
$0.42 |
$8,407 |
D/D |
20,000 |
30,000 |
2.39 |
% |
|
| DRRX |
Durect Corp |
Director |
– • – |
2022-05-16 |
4 |
B |
$0.38 |
$3,767 |
D/D |
10,000 |
10,000 |
2.31 |
% |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2021-12-15 |
4 |
OE |
$3.67 |
$11,326 |
D/D |
3,086 |
66,819 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2020-12-15 |
4 |
OE |
$3.76 |
$11,603 |
D/D |
3,086 |
63,733 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2019-12-16 |
4 |
OE |
$3.56 |
$10,986 |
D/D |
3,086 |
60,647 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2019-09-13 |
4 |
S |
$9.31 |
$214 |
D/D |
(23) |
57,561 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2018-12-06 |
4 |
OE |
$3.07 |
$9,474 |
D/D |
3,086 |
57,584 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2018-06-21 |
4 |
OE |
$3.70 |
$38,066 |
D/D |
10,288 |
54,498 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2017-11-15 |
4 |
B |
$2.22 |
$33,281 |
D/D |
15,000 |
44,210 |
2.39 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2017-09-22 |
4 |
B |
$2.95 |
$23,600 |
D/D |
8,000 |
29,210 |
2.39 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2017-09-21 |
4 |
B |
$2.95 |
$5,900 |
D/D |
2,000 |
21,210 |
2.39 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2017-08-18 |
4 |
B |
$2.90 |
$18,302 |
D/D |
6,312 |
19,210 |
2.39 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2017-08-17 |
4 |
B |
$2.65 |
$61 |
D/D |
23 |
12,898 |
2.31 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2016-12-01 |
4 |
OE |
$3.21 |
$39,627 |
D/D |
12,345 |
17,283 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2016-12-01 |
4 |
D |
$7.80 |
$34,382 |
D/D |
(4,408) |
12,875 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2015-12-11 |
4 |
OE |
$5.22 |
$12,888 |
D/D |
2,469 |
4,938 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2015-01-08 |
4 |
OE |
$4.98 |
$12,296 |
D/D |
2,469 |
2,469 |
0 |
- |
|
| ASTX |
Astex Pharmaceuticals Inc |
Chief Medical Officer |
• – – |
2013-10-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(8,753) |
0 |
0 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
Exec VP-R&D, CMO |
• – – |
2005-05-24 |
4 |
B |
$10.28 |
$10,276 |
D/D |
1,000 |
1,200 |
2.74 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
